UAE Bans Veterinary Use of Ciprofloxacin to Combat Antimicrobial Resistance

This regulatory action is a critical step in combating antimicrobial resistance, which poses a significant threat to global public health.

• The Emirates Drug Establishment (EDE) announced a ban on veterinary use of ciprofloxacin effective November 1, 2026.
• Nine products containing ciprofloxacin, including eight imported and one locally registered, will be prohibited.
• Compliance monitoring is being developed to ensure adherence to the new regulations.

• Antimicrobial resistance (AMR) is responsible for an estimated 4.7 million global deaths in 2021, highlighting the urgency of addressing this issue.
• Ciprofloxacin is classified as a Critically Important Antimicrobial for treating severe human infections, making its preservation vital for public health.
• The UAE's decision aligns with international efforts to regulate antimicrobial use in veterinary medicine to prevent the acceleration of resistance.

On October 20, 2026, the Emirates Drug Establishment (EDE) took a decisive step to ban the veterinary use of ciprofloxacin, a fluoroquinolone antibiotic. This action is rooted in a growing body of evidence indicating that inappropriate use of such antibiotics in animals can lead to increased antimicrobial resistance (AMR), which poses a significant threat to human health. The decision follows a comprehensive scientific assessment, including studies from UAE University, which highlighted concerning patterns of resistance.

Ciprofloxacin is widely used in both human and veterinary medicine, but its effectiveness is jeopardized when used indiscriminately in animals. The EDE's ban aims to preserve the antibiotic's efficacy for treating severe human infections, such as sepsis and pneumonia. By prohibiting the manufacturing, importation, supply, and use of ciprofloxacin-containing veterinary products, the UAE is taking a proactive stance against AMR.

The ban affects nine specific products, with directives issued to manufacturers and importers to cease operations and withdraw existing stocks from the market by the effective date. This regulatory measure is part of a broader national strategy to promote responsible antimicrobial use across various sectors, reflecting a commitment to public health and safety.

As the EDE develops a compliance monitoring plan, it is crucial to note that no immediate market disruptions or stakeholder objections have been reported. This smooth transition suggests that the veterinary sector is prepared to adapt to the new regulations. Pet owners and farms will need to consult with veterinarians to identify alternative antimicrobials, but initial reports indicate no shortages or price impacts.

The UAE's ban on veterinary ciprofloxacin is not just a local issue; it resonates with global health initiatives aimed at mitigating AMR. The One Health approach, which recognizes the interconnectedness of human, animal, and environmental health, underscores the importance of such regulatory actions. By addressing the veterinary use of critical antibiotics, the UAE is contributing to a global effort to safeguard public health and ensure the continued effectiveness of essential medications.

• Veterinary professionals will need to adjust treatment protocols and recommend alternative antimicrobials.
• Pet owners may face changes in prescribed medications for their animals, requiring consultation with veterinarians.
• Livestock farmers will need to transition to different antimicrobial options, impacting their operational practices.
• Importers and manufacturers of veterinary products will have to comply with new regulations, affecting their business models.

• Compliance monitoring outcomes: Observing how effectively the EDE enforces the ban will indicate the UAE's commitment to combating AMR.
• Market adaptation: Watch for how quickly veterinary professionals and product suppliers adapt to the new regulations and what alternatives emerge.
• Global response: The UAE's actions may inspire similar regulatory measures in other countries, influencing international standards for antimicrobial use.